Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Depreciation and Depletion (2021 - 2025)

Historic Depreciation and Depletion for Krystal Biotech (KRYS) over the last 5 years, with Q4 2025 value amounting to $1.5 million.

  • Krystal Biotech's Depreciation and Depletion rose 909.09% to $1.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $5.6 million, marking a year-over-year decrease of 489.53%. This contributed to the annual value of $5.7 million for FY2025, which is 460.0% down from last year.
  • As of Q4 2025, Krystal Biotech's Depreciation and Depletion stood at $1.5 million, which was up 909.09% from $1.4 million recorded in Q3 2025.
  • Krystal Biotech's 5-year Depreciation and Depletion high stood at $1.8 million for Q2 2024, and its period low was $438000.0 during Q1 2021.
  • Moreover, its 5-year median value for Depreciation and Depletion was $1.2 million (2023), whereas its average is $1.1 million.
  • In the last 5 years, Krystal Biotech's Depreciation and Depletion skyrocketed by 14291.5% in 2023 and then crashed by 2777.78% in 2025.
  • Over the past 5 years, Krystal Biotech's Depreciation and Depletion (Quarter) stood at $449000.0 in 2021, then surged by 132.29% to $1.0 million in 2022, then skyrocketed by 44.49% to $1.5 million in 2023, then decreased by 7.3% to $1.4 million in 2024, then rose by 9.09% to $1.5 million in 2025.
  • Its Depreciation and Depletion was $1.5 million in Q4 2025, compared to $1.4 million in Q3 2025 and $1.3 million in Q2 2025.